BioXcel Therapeutics (BTAI) Misses Q1 EPS by 129c
Tweet
Share
E-mailGet Alerts BTAI Hot Sheet
Join SI Premium – FREE
BioXcel Therapeutics (NASDAQ: BTAI) reported Q1 EPS of ($1.50), $1.29 worse than the analyst estimate of ($0.21). Revenue for the quarter came in at $168 thousand versus the consensus estimate of $400 thousand.
For earnings history and earnings-related data on BioXcel Therapeutics (BTAI) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BofA maintains underperform ratings on six BDC stocks
- Kimbell Royalty closes $221.2M mineral rights acquisition
- BofA says CTA Treasury shorts stable, euro short-cover risk rises
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
